Y-Biologics (XKRX:338840) Change In Receivables : ₩-342 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Change In Receivables?

Y-Biologics's change in receivables for the quarter that ended in Mar. 2024 was ₩13 Mil. It means Y-Biologics's Accounts Receivable declined by ₩13 Mil from Dec. 2023 to Mar. 2024 .

Y-Biologics's change in receivables for the fiscal year that ended in Dec. 2022 was ₩755 Mil. It means Y-Biologics's Accounts Receivable declined by ₩755 Mil from Dec. 2021 to Dec. 2022 .

Y-Biologics's Accounts Receivable for the quarter that ended in Mar. 2024 was ₩310 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Y-Biologics's Days Sales Outstanding for the three months ended in Mar. 2024 was 24.77.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Y-Biologics's liquidation value for the three months ended in Mar. 2024 was ₩13,145 Mil.

Y-Biologics Change In Receivables Historical Data

The historical data trend for Y-Biologics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Change In Receivables Chart

Y-Biologics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-207.02

9.89

-4,361.86

2,594.00

754.88

Y-Biologics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial				-	-	26.33	-381.48	13.09

Y-Biologics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-342 Mil.

Y-Biologics (XKRX:338840) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Y-Biologics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	310.123	/	1142.665	*	91
=	24.77

2. In Ben Graham's calculation of liquidation value, Y-Biologics's accounts receivable are only considered to be worth 75% of book value:

Y-Biologics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	17358.659	-	4445.885	+	0.75 * 310.123	+	0.5 * 0
=	13,145

Y-Biologics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Y-Biologics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-Biologics (XKRX:338840) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR

Website

https://www.ybiologics.com

Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines